Table 2. The association of OGT, OGA or O-GlcNAc levels and clinicopathological features of patients in cohort B.
| Clinicopathological characteristics (Total n =201) | OGT | P values | OGA | P values | O-GlcNAc | P values | |||
|---|---|---|---|---|---|---|---|---|---|
| Low (n = 94) | High (n = 107) | Low (n = 148) | High (n = 53) | Low (n = 51) | High (n = 150) | ||||
| Age (years) | |||||||||
| Mean (±SD) | 65.0 (±11.9) | 65.7 (±10.4) | 0.661a | 65.0 (±11.2) | 66.6 (±10.9) | 0.361a | 63.8 (±11.7) | 65.9 (±10.9) | 0.238a |
| Range | 35-88 | 38-83 | 35-83 | 37-88 | 37-83 | 35-88 | |||
| Sex | |||||||||
| Male | 52 (55.3%) | 64 (59.8%) | 0.520b | 83 (56.1%) | 33 (62.3%) | 0.434b | 29 (56.9%) | 87 (58.0%) | 0.887b |
| Female | 42 (44.7%) | 43 (40.2%) | 65 (43.9%) | 20 (37.7%) | 22 (43.1%) | 63 (42.0%) | |||
| Follow-up time, months | |||||||||
| Mean (±SD) | 54.1 (±22.5) | 47.4 (±26.1) | 0.056a | 52.8 (±24.0) | 44.2 (±25.6) | 0.029a* | 54.8 (±29.1) | 49.1 (±22.9) | 0.158a |
| Range | 3.03-99.97 | 1.20-100.43 | 4.63-100.43 | 1.20-89.50 | 3.53-99.97 | 1.20-100.43 | |||
| Disease stage† | |||||||||
| Stage I | 59 | 54 | 0.181b | 86 | 27 | 0.823b | 29 | 84 | 0.482b |
| Stage II | 6 | 12 | 12 | 5 | 7 | 11 | |||
| Stage III | 22 | 35 | 40 | 17 | 12 | 45 | |||
| Stage IV | 6 | 4 | 8 | 2 | 2 | 8 | |||
| Unknown | 1 | 2 | 1 | 2 | 1 | 2 | |||
| Disease stage group† | |||||||||
| Stage I | 59 (63.4%) | 54 (51.4%) | 0.088b | 86 (58.5%) | 27 (52.9%) | 0.489b | 29 (58.0%) | 84 (56.8%) | 0.878b |
| Stage II/III/IV | 34 (36.6%) | 51 (48.6%) | 61 (41.5%) | 24 (47.1%) | 21 (42.0%) | 64 (43.2%) | |||
| Unknown | 1 | 2 | 1 | 2 | 1 | 2 | |||
| EGFR status† | |||||||||
| Wild-type | 32 (40.5%) | 44 (47.3%) | 0.370b | 59 (46.1%) | 17 (38.6%) | 0.390b | 23 (54.8%) | 53 (40.8%) | 0.112b |
| Mutant | 47 (59.5%) | 49 (52.7%) | 69 (53.9%) | 27 (61.4%) | 19 (45.2%) | 77 (59.2%) | |||
| Unknown | 15 | 14 | 20 | 9 | 9 | 20 | |||
| Histiological subtype† | |||||||||
| Lepidic | 18 | 14 | 0.287b | 23 | 9 | 0.056b | 9 | 23 | 0.197b |
| Acinar | 31 | 45 | 59 | 17 | 24 | 52 | |||
| Papillary | 19 | 13 | 27 | 5 | 10 | 22 | |||
| Micropapillary | 11 | 11 | 11 | 11 | 3 | 19 | |||
| Solid | 14 | 21 | 24 | 11 | 5 | 30 | |||
| Unknown | 1 | 3 | 4 | 0 | 0 | 4 | |||
| Histiological subtype group† | |||||||||
| Lepidic/acinar/papillary | 68 (73.1%) | 72 (69.2%) | 0.548b | 109 (75.7%) | 31 (58.5%) | 0.018b* | 43 (84.3%) | 97 (66.4%) | 0.015b* |
| Micropapillary/solid | 25 (26.9%) | 32 (30.8%) | 35 (24.3%) | 22 (41.5%) | 8 (15.7%) | 49 (33.6%) | |||
| Unknown | 1 | 3 | 4 | 0 | 0 | 4 | |||
SD, standard deviation. a. independent samaples t-test b. two-tailed Pearson’s chi-squared test †, Patients with unknown status were excluded in the analysis *, P <0.05.